EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Annals of the Rheumatic Diseases (ARD)
is a leading rheumatology journal from EULAR, publishing original research, reviews and recommendations
Impact Factor: 27.4
Citescore: 32.8
All metrics >>
Latest EULAR Recommendations
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update
2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome
EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Editor's Choice
Rheumatoid arthritis:
Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study24 July 2023
Latest Articles
Autoinflammatory disorders:
Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies1 December 2023
Vasculitis:
Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasus arteritis, ANCA-associated vasculitis and giant cell arteritis29 November 2023
Rheumatoid arthritis:
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation27 November 2023
Early arthritis:
Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres27 November 2023
Recommendations
The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.
All EULAR recommendations are free to access.
Each recommendation also has an accompanying lay summary, which is also free to access.
Video
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
Conclusion: At Week 52, dual inhibition of IL-17A and IL-17F with BKZ resulted in sustained efficacy across the axSpA spectrum; the safety profile was consistent with the known safety of BKZ.
Find out moreAltmetrics
Jobs
Perth and Kinross
NHS Tayside Consultant in Child & Adolescent Psychiatry 40 Hours per week We have an exciting opportunity available in one of the UK’s most up an...Recruiter: NHS Tayside
Salaried General Practitioner
Richmond, North Yorkshire
We are looking for an enthusiastic and motivated individual to join our close-knit team where humour and mutual support are valuedRecruiter: Quakers Lane Surgery
Specialty Doctor in Musculoskeletal and Sport and Exercise Medicine
Leicester
We are pleased to offer an opportunity to apply for one of our established GP/Speciality Dr posts working in the Leicester Hospital Sports MedicineRecruiter: University Hospitals of Leicester NHS Trust
GP Partner
Southwark, London (Greater)
We are looking for new GP Partners who will bring fresh ideas, enthusiasm and commitment to our partnership in Southwark.Recruiter: Nexus Health Group
Consultant Geriatric Medicine
Guildford
Looking to appoint Consultant Geriatrician to work in our evolving Hospital at Home service. This is a substantive post.Recruiter: The Royal Surrey NHS Foundation Trust